Focus:
News
-
7 August 2020
ACTT 3 trial evaluates remdesivir plus interferon beta-1a
The US National Institutes of Health (NIH) has launched the ACTT 3 clinical trial to evaluate Gilead Sciences' remdesivir in combination with interferon beta-1a, an immunomodulator, to treat Covid-19 in...
-
7 August 2020
Daiichi Sankyo and AstraZeneca partner on lung cancer trial
Daiichi Sankyo and AstraZeneca have partnered to assess patritumab deruxtecan (U3-1402) in combination with Tagrisso (osimertinib) for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).
-
6 August 2020
IMV receives funding for trials of its Covid-19 vaccine candidate
Clinical-stage biopharmaceutical company IMV has announced that the government agencies of Canada will invest up to C$4.75m ($3.58m) in IMV’s Covid-19 vaccine candidate DPX-Covid-19.
-
6 August 2020
Pfizer says Lorbrena met primary goal in lung cancer trial
Pfizer has reported positive results from the Phase III CROWN clinical trial of Lorbrena (lorlatinib) in patients with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
-
6 August 2020
BioNTech and Fosun Pharma trial Covid-19 vaccine in China
BioNTech and Shanghai Fosun Pharmaceutical have started dosing participants in a Phase I clinical trial of Covid-19 vaccine candidate, BNT162b1.
-
6 August 2020
Zydus Cadila’s Covid-19 vaccine enters Phase II testing
India-based Zydus Cadila has launched Phase II clinical trials of its Covid-19 vaccine candidate, ZyCoV-D, which showed promise in a Phase I study.
-
5 August 2020
Investment firm GI Partners to acquire minority interest in Clinical Ink
Private equity investment firm GI Partners has announced that it will acquire a minority interest in global clinical trial technology Clinical Ink.
-
5 August 2020
NIH starts trial of antibody treatments for Covid-19 patients
The US National Institutes of Health (NIH) has initiated a Phase III clinical trial, named ACTIV-3, to evaluate various types of monoclonal antibodies as potential treatments for hospitalised Covid-19 patients.
-
5 August 2020
Novartis’ Kymriah shows benefit in follicular lymphoma patients
Novartis has reported positive data from the Phase II ELARA clinical trial of Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL).
-
5 August 2020
COVID-19 poll: Disrupted clinical trials will take six to 12 months to return to normal
The COVID-19 pandemic significantly disrupted ongoing clinical trials in various stages, with more than 1,000 trials by sponsors, collaborators, or contract research organisations having gone off the trial schedules.